Phoenix PharmaLabs

Phoenix PharmaLabs

About this raise

Phoenix PharmaLabs, with a post-money valuation of $26,790,283, iis Testing the Waters on NetCapital. The company is a preclinical drug discovery company dedicated to the development of potent, safe, non-addictive treatments for pain and addiction. John Lawson, PH.D. and Lawrence Toll, PH.D. founded Phoenix PharmaLabs. The crowdfunding round has a minimum raise of $10,000 and a maximum raise of $1,070,000. Phoenix PharmaLabs lead drug, PPL-103, has demonstrated in animal studies that it is a very potent painkiller (10x more potent than morphine), and is non-addictive, does not produce withdrawal, does not cause death from overdose at elevated doses, and causes no constipation.

Expand

Investment Overview

Invested this round: $0

Deal Terms

Total Commitments ($USD)

Platform
Netcapital
Start Date
12/24/2020
Close Date
01/30/2021
Min. Goal
Funded
Max Goal
Funded
Min. Investment

$99

Security Type

Equity - Common

Series

Seed

SEC Filing Type

Test the Waters    Open SEC Filing

Price Per Share

$1.00

Pre-Money Valuation

$26,790,283

Company & Team

Company

Year Founded
2002
Industry
Healthcare & Pharmaceuticals
Tech Sector
HealthTech
Distribution Model
B2B2C
Margin
High
Capital Intensity
High
Location
Woods Cross, Utah
Business Type
Growth
Company Website
Visit Website

Team

Employees
4
Founder Name
John A Lawson
Title
Chairman and Chief Scientific Officer
Founder Name
Lawrence Toll
Title
Chief Neuropharmacologist and Board Member

Funding data not publicly available

Financials

 Revenue +1,828% YoY
$1,285,068
 Monthly Burn
$39,829
 Runway
0 months
Create a free account today to gain access to Kingscrowd analytics and financials.

Upgrade to gain access

Pay Monthly
Annually (2 months free)

Edge

$12.50 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific Kingscrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Company Funding & Growth

Funding history

Close Date Platform Valuation Total Raised Security Type Status Reg Type
06/18/2021 Netcapital $26,790,283 $1,065,500 Equity - Common Funded RegCF
01/30/2021 Netcapital $26,790,283 $0 Equity - Common Funded Test the Waters
03/30/2019 Netcapital $23,136,335 $1,102,553 Equity - Common Funded RegCF / RegD 506(c)
Create a free account today to gain access to Kingscrowd analytics.

Growth Charts

Revenue History

Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.

Valuation History

Price per Share History

Note: Share prices shown in earlier rounds may not be indicative of any stock splits.

Employee History

Founders: enhance your startup's credibility on Kingscrowd. Create an account to claim this raise page.
Add to portfolio
Phoenix PharmaLabs on Netcapital
Platform: Netcapital
Security Type: Equity - Common
Valuation: $26,790,283
Price per Share: $1.00

Follow company

Follow Phoenix PharmaLabs on Netcapital

Buy Phoenix PharmaLabs's Deal Report

Warning: according to the close date for this deal, Phoenix PharmaLabs may no longer be accepting investments.

Phoenix PharmaLabs Deal Report

Get Kingscrowd's comprehensive report on Phoenix PharmaLabs including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether Phoenix PharmaLabs is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the Phoenix PharmaLabs deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge